157 related articles for article (PubMed ID: 7882387)
21. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
22. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.
Bernhard H; Roth S; Bauerschmitz J; Meyer zum Büschenfelde KH; Dippold W
Int J Cancer; 1992 Jun; 51(4):568-72. PubMed ID: 1376299
[TBL] [Abstract][Full Text] [Related]
23. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity.
Natoli EJ; Livingston PO; Pukel CS; Lloyd KO; Wiegandt H; Szalay J; Oettgen HF; Old LJ
Cancer Res; 1986 Aug; 46(8):4116-20. PubMed ID: 3731079
[TBL] [Abstract][Full Text] [Related]
24. Carbohydrate antigens as targets for active specific immunotherapy.
Ragupathi G
Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568
[TBL] [Abstract][Full Text] [Related]
25. Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues.
Brezicka T; Bergman B; Olling S; Fredman P
Lung Cancer; 2000 Apr; 28(1):29-36. PubMed ID: 10704706
[TBL] [Abstract][Full Text] [Related]
26. Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo.
Nishio M; Furukawa K
Nagoya J Med Sci; 2004 May; 67(1-2):35-44. PubMed ID: 15279066
[TBL] [Abstract][Full Text] [Related]
27. Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA.
Ravindranath MH; Bauer PM; Cornillez-Ty C; Garcia J; Morton DL
J Immunol Methods; 1996 Oct; 197(1-2):51-67. PubMed ID: 8890894
[TBL] [Abstract][Full Text] [Related]
28. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
29. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
30. Recognition of cell surface GD3 by monoclonal antibody anti-6C2 in rheumatoid arthritis synovial fluid: expression on human T cells with transendothelial migratory activity.
Homma T; Hosono O; Iwata S; Ando S; Sasaki K; Nishi T; Kawasaki H; Tanaka H; Morimoto C
Arthritis Rheum; 2001 Feb; 44(2):296-306. PubMed ID: 11229459
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas.
Bosslet K; Mennel HD; Rodden F; Bauer BL; Wagner F; Altmannsberger A; Sedlacek HH; Wiegandt H
Cancer Immunol Immunother; 1989; 29(3):171-8. PubMed ID: 2471592
[TBL] [Abstract][Full Text] [Related]
32. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice.
Katano M; Irie RF
Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067
[TBL] [Abstract][Full Text] [Related]
33. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
[TBL] [Abstract][Full Text] [Related]
34. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma.
Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R
Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of melanoma-associated gangliosides in cancer patients.
Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
[TBL] [Abstract][Full Text] [Related]
36. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.
Zhang S; Cordon-Cardo C; Zhang HS; Reuter VE; Adluri S; Hamilton WB; Lloyd KO; Livingston PO
Int J Cancer; 1997 Sep; 73(1):42-9. PubMed ID: 9334808
[TBL] [Abstract][Full Text] [Related]
37. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.
Helfand SC; Dickerson EB; Munson KL; Padilla ML
Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254
[TBL] [Abstract][Full Text] [Related]
38. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
39. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
40. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
